The primary objective of this project is to develop an effective, peptide-based nicotine vaccine for use in humans capable of inducing a robust, nicotine-specific antibody (Ab) response with little or no inflammatory side effects. This will be accomplished by vaccine designs in which conformationally biased, response-selective agonists of C5a (YSFKPMPLaR and YSFKDMP(MeL)a) are used as molecular adjuvants and a nicotine hapten is used as the target antigen (Ag). The ability of such molecular adjuvant-containing vaccines to induce an anti-nicotine immune response will be assessed by two general methods. The first is to characterize the molecular and cellular mechanisms by which the molecular adjuvants engage C5a receptor (C5aR)-bearing antigen presenting cells (APC) to enhance the APCs' ability to process and present the nicotine Ag. The second is to vaccinate rats with molecular adjuvant-containing nicotine vaccines in the absence of added adjuvant and demonstrate the presence of nicotine-specific Abs in immune sera/tissues and an attenuation of nicotine-induced behavioral effects in two well-established rat models of nicotine dependence. Validation of these peptide-based, molecular adjuvant-containing nicotine vaccines represents the first step toward realization of the broad objective sought by this project, which is to use vaccination to nicotine with such vaccines as a standard therapeutic regimen for smoking cessation and maintenance of long term compliance. The first steps toward this broad objective will be taken with the following specific aims: 1) To characterize the cellular and molecular mechanisms by which the molecular adjuvants YSFKPMPLaR and YSFKDMP(MeL)aR engage C5aR-bearing human APCs such that these cells are activated and their Ag processing/presenting capacity is enhanced. 2) To test YSFKPMPLaR- and YSFKDMP(MeL)aR-containing nicotine vaccines for their ability to induce anti-nicotine immune responses in rats without the use of added adjuvants, and 3) To test whether vaccination with YSFKPMPLaR- and YSFKDMP(MeL)aR-containing vaccines attenuates the behavioral effects of nicotine in well-characterized rat models of nicotine dependence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102259-03
Application #
7090875
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Djordjevic, Mirjana V
Project Start
2004-07-20
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2008-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$227,815
Indirect Cost
Name
University of Nebraska Medical Center
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Bevins, Rick A; Wilkinson, Jamie L; Sanderson, Sam D (2008) Vaccines to combat smoking. Expert Opin Biol Ther 8:379-83
Hegde, Ganapati V; Meyers-Clark, Erin; Joshi, Shantaram S et al. (2008) A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. Int Immunopharmacol 8:819-27